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Epithelial Cells Promote Fibroblast Activation
via IL-1a in Systemic Sclerosis
Nima Aden1,3, Anna Nuttall1,3, Xu Shiwen1, Patricia de Winter1, Andrew Leask2, Carol M. Black1,
Christopher P. Denton1, David J. Abraham1 and Richard J. Stratton1
Systemic sclerosis (SSc) is a disorder of systemic and dermal fibrosis of uncertain etiology. Recently, we found
that SSc epidermis is abnormal, taking on an activated phenotype observed during wound healing and tissue
repair. As epithelial–fibroblast interactions are important during wound repair and in fibrosis in general, we
investigated further the phenotype of the SSc epidermis, and tested whether the SSc epidermis provides a pro-
fibrotic stimulus to fibroblasts. In this study we show that in SSc epidermis keratinocyte maturation is delayed,
and wound-associated keratins 6 and 16 are induced, in both involved and clinically uninvolved skin.
Phosphorylation array analysis revealed induction of stress-induced mitogen-activated protein kinase signaling
and mesenchymal feedback through hepatocyte growth factor/c-Met in SSc epidermis. SSc epidermal cells
maintained with normal fibroblasts in three-dimensional co-culture were found to stimulate fibroblasts, leading
to contractility and connective tissue growth factor expression. These effects depend on elevation of IL-1a by
the epidermal cells and induction of endothelin-1 and transforming growth factor-b in fibroblasts. Antagonism
of endogenous IL-1a using IL-1 receptor antagonist blocked gel contraction by SSc epidermis. We propose that
in SSc, epidermal cells are in a persistently activated state and are able to promote dermal fibrosis. These
findings are important because biologic therapies could target epithelial–fibroblast interactions in the disease.
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INTRODUCTION
Systemic sclerosis (scleroderma (SSc)) is a systemic fibrotic
disease of uncertain etiology that affects 250 per million of
population. SSc is characterized by autoimmune phenomena,
vascular injury, and fibrosis of the skin and certain internal
organs (Varga and Abraham, 2007). The skin lesions in SSc
are disfiguring and disabling, and life expectancy is reduced
because of organ fibrosis or vascular lesions (Steen and
Medsger, 2007). Fibroblast activation is thought of as key to
SSc pathogenesis (Jimenez and Bashey, 1977). Fibroblasts in
lesional skin of patients with SSc persist as myofibroblasts,
and in culture have an enhanced ability to produce, adhere
to, and contract extracellular matrix (Jimenez et al., 1986).
A number of mechanisms have been proposed to account
for SSc fibrosis, including persistent and inappropriate
expression of fibrosis-enhancing growth factors (Sato et al.,
2000), fibroblast stimulation by autoantibodies (Baroni et al.,
2006), and signaling to fibroblasts by immune activated
endothelial cells.
Transforming growth factor-b (TGF-b) is implicated
in fibrosis in general and has been studied in SSc. TGF-b is
regulated largely by post-translational events, requiring
cleavage from an inactive form bound to latency-associated
peptide. Free TGF-b dimers bind type I and type II receptors
(TbRI and II) forming hexamers, which induce the phosphor-
ylation of receptor-associated SMAD proteins, which in turn
initiate signal transduction (Wrana et al., 1994; Johnson et al.,
1999; Shi and Massague´, 2003). TGF-b signal transduction
has been studied in SSc, revealing increased phosphorylation
of SMAD proteins in SSc fibroblasts (Mori et al., 2003),
altered expression of regulatory SMAD7 (Dong et al., 2002),
and an increased ratio of type I to type II TGF-b receptors
(Pannu et al., 2004). Gene array analysis confirms fibroblast
activation in the disease with overexpression of TGF-b-
induced genes, including extracellular matrix genes, fibro-
blast-associated genes, and genes involved in the contractility
of myofibroblasts (Whitfield et al., 2003). The events leading
to TGF-b induction and the induction of TGF-b-dependent
gene expression in SSc fibroblasts are not understood.
Other fibrosis-enhancing growth factors downstream of
TGF-b are persistently upregulated in the disease, including
connective tissue growth factor (CTGF) and endothelin-1 (ET-1)
(Vancheeswaran et al., 1994a). CTGF is a member of the CCN
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family that is induced by TGF-b and is implicated in many
fibrotic disorders (Frazier et al., 1996). CTGF is elevated in
plasma and dermal interstitial fluid from SSc patients, and
levels of the N-terminal peptide fragment of CTGF correlate
with severity of skin fibrosis and inversely with disease duration
(Dziadzio et al., 2005). ET-1 has a well-established role in
fibrosis and fibroblast activation (Hocher et al., 2000), and
increased plasma and tissue ET-1 levels are observed in SSc
patients (Vancheeswaran et al., 1994b). The ability of SSc lung
fibroblasts to express pro-contractile proteins and contract
three-dimensional collagen lattices is greatly reduced by
antagonizing ET-1 signaling (Shi-Wen et al., 2004).
Most previous studies give emphasis to alterations in the
dermis of SSc skin. Changes in skin pigmentation, which can
be severe and involve large areas of the skin, are a frequent
observation in SSc, and imply that the epidermis is involved
in the disease process (Tabata et al., 2000). Recently, we
showed that in SSc the epidermal cell layer is highly
abnormal, as keratinocytes in the epidermis express a
phenotype usually restricted to the wound healing environ-
ment (Aden et al., 2008). Keratinocytes activated during
wound repair release growth factors and cytokines that
stimulate fibroblasts and endothelial cells, initiate the influx
of inflammatory cells, and produce systemic effects (Shep-
hard et al., 2004; Werner et al., 2007).
In addition, epithelial–fibroblast interactions are consid-
ered to be important in fibrosis. For example, in idiopathic
lung fibrosis, multiple cycles of epithelial injury and
activation by environmental agents are considered to injure
epithelial cells, which in turn recruit and activate fibroblasts
leading to fibrosis. The resulting active alveolar epithelial
cells induce migration, proliferation, and activation of the
underlying fibroblastic cells. The formation of fibroblastic/
myofibroblastic foci and the exaggerated accumulation of
extracellular matrix that ensues mirrors abnormal wound
repair and accounts for the disease pathogenesis (Selman and
Pardo, 2002). Epithelial–fibroblast interactions are also
implicated in keloid formation because co-culture of keloid
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Figure 1. Keratin expression in systemic sclerosis (SSc) and control epidermis. (a) Skin biopsy material from the involved forearm skin or clinically uninvolved
interscapular skin of SSc patients (n¼ 6) and from the forearm skin of healthy controls (n¼ 6) were stained for keratin markers of differentiation. Keratin 14 (K14)
was confined to basal cell layer in healthy control epidermis but expressed in suprabasal layer and above in SSc, consistent with altered differentiation in SSc
keratinocytes. K6 and K16, normally restricted to wound healing environments, were expressed by epidermal cells in SSc. The abnormalities of keratinocyte
differentiation were observed in both involved forearm biopsy material and in clinically uninvolved interscapular tissue. (b) IL-1a, endothelin-1 (ET-1), and
transforming growth factor-b (TGF-b) were measured by ELISA of epidermal biopsy material from SSc patients (n¼6) and healthy controls (n¼6). IL-1a levels were
greatly increased in SSc epidermal layer. ET-1 and TGF-b levels were not altered in the disease epidermis. Original magnification  40, scale bar¼100mm.
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keratinocytes with normal dermal fibroblasts results in
upregulation of mRNA for collagen type I and III, increased
fibroblast proliferation, and extracellular matrix accumula-
tion (Xia et al., 2004).
Because of the above findings, we have become interested
in the role of the epidermis in SSc pathogenesis, and in the
possibility that keratinocyte–fibroblast interactions are con-
tributing to SSc skin fibrosis. We use epidermal cell layers
obtained from skin biopsies from SSc patients cultured in
fibroblast populated three-dimensional collagen gels to
investigate possible mechanisms by which keratinocytes are
promoting fibroblasts in the disease.
RESULTS
Delayed maturation and induction of keratins 6 and 16 in the
epidermis in SSc
First, we confirmed the phenotype of the epidermal layer
obtained from SSc and controls (both n¼ 6). The disease
epidermis was found to be expanded and showed delayed
maturation with abnormal persistence of basal keratin 14
(K14). In addition, K6 and K16, normally restricted to wound
healing epidermis, were strongly expressed in SSc epidermal
layer. These changes were observed in material from both
involved forearm skin and clinically uninvolved skin (Figure 1).
Because induction of IL-1a is considered an important
initiating stimulus to keratinocyte activation we measured
total IL-1a in SSc (n¼6) and healthy control (n¼6)
epidermal cell layers by ELISA. ET-1, free TGF-b, and TGF-b
associated with latency-associated peptide were also mea-
sured for comparison. IL-1a levels were increased in the SSc
epidermal layers compared with controls, whereas ET-1 and
TGF-b levels did not differ between SSc and control
epidermis (Figure 1).
SSc epidermis promotes fibroblast contractility and CTGF
expression via IL-1
As epidermal keratinocytes activated by injury are known to
promote wound fibroblast differentiation, we determined
whether the activated epidermal layer in scleroderma skin
had the capacity to stimulate fibroblasts in vitro. Three-
dimensional co-culture of the epidermis from SSc patients
(n¼6) with normal human fibroblasts was found to promote
fibroblast ability to contract fibroblast-populated collagen
lattices (FPCLs) to the extent observed with TGF-b, a known
enhancer (Figure 2). Epidermis from healthy controls (n¼ 6)
did not promote contraction of FPCLs above background. We
went on to measure expression of CTGF by fibroblasts within
the FPCLs, because CTGF is a marker of fibroblast activation
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Figure 2. Activation of normal dermal fibroblasts by systemic sclerosis (SSc) epidermal cells. (a) Normal dermal fibroblasts in fibroblast-populated collagen
lattices (FPCLs) were co-cultured with SSc epidermal cell layer from involved forearm skin (n¼6), healthy control epidermis (n¼ 6), or transforming growth
factor-b (TGFb; 4 ngml–1), or with medium only for 48 hours. Gel diameter was measured by photography and fibroblasts were lysed for western analysis.
(b) Co-culture with SSc epidermal cell layer and treatment with TGF-b lead to FPCL contraction at 48 hours. (c) Induction of connective tissue growth factor
(CTGF) in fibroblasts was observed after co-culture with SSc epidermal cells and exposure to TGF-b.
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in SSc and of the pro-fibrotic phenotype in general. Co-
culture with SSc epidermal layer led to the induction of CTGF
in FPCLs. As expected, treatment with 4 ngml–1 TGF-b also
caused CTGF induction. CTGF was present only at low levels
in control untreated FPCLs and in FPCLs co-cultured with
control epidermal cell layers (Figure 2).
Because we had found IL-1a to be elevated in SSc
epidermis, and because IL-1a is believed to initiate keratino-
cyte–fibroblast interactions during wound healing, we mea-
sured the effect of IL-1 receptor antagonist (IL-1ra) on
fibroblast activation by SSc epidermis. FPCLs were
co-cultured with epidermal layer from SSc patients (n¼ 4)
in the presence or absence of IL-1ra (100 nM). The SSc
epidermis promoted FPCL contraction at 48 hours, which was
antagonized by the presence of IL-1ra (Figure 3). Co-culture
of FPCLs with SSc epidermis did not seem to be inducing
IL-1a in the fibroblasts (Figure 3). We concluded that the SSc
epidermal cells are the source of IL-1a responsible for
initiating fibroblast activation during co-culture.
FPCL contraction by SSc epidermal cells requires induction of
ET-1 and TGF-b by fibroblasts
Because epithelial–fibroblast interactions during wound
repair are known to depend on autocrine stimulation of
fibroblasts by TGF-b and ET-1, we measured the induction of
these factors in FPCLs after incubation with SSc epidermis, as
well as the effect of antagonism of these factors. Co-culture of
FPCLs with SSc epidermis (n¼ 3) led to induction of both
ET-1 and TGF-b in fibroblasts (Figure 4). Addition of ETA and
ETB inhibitor bosentan (10 mM) to the gels prevented SSc
epidermis-induced contraction of FPCLs. In addition, bosen-
tan inhibited the induction of ET-1 in fibroblasts after co-
culture with SSc epidermis and after treatment with TGF-b,
consistent with an autocrine loop of ET-1 induction in the
fibroblasts (Figure 4). Antagonism of TGF-b by neutralizing
anti-TGF-b antibody 1d11 (1mgml–1) blocked FPCL contrac-
tion by SSc epidermis (n¼ 3) and TGF-b (Figure 4). We
concluded that fibroblast activation by SSc epidermal cells
requires the induction of ET-1 and TGF-b, produced by
fibroblasts.
Stress response signaling pathways are induced in SSc
epidermal layer
Phosphorylation arrays were performed on the epidermal
tissue from SSc patients (n¼4) and healthy controls (n¼ 4) to
identify signaling pathways activated in SSc epidermis
(Tables 1 and 2). A number of proteins were found to have
elevated phosphorylation states in SSc tissues versus controls,
including stress-induced mitogen-activated protein kinase
(MAPK) pathways (c-Jun and p38 signal transduction path-
way). Phosphorylated c-Met (hepatocyte growth factor (HGF)
receptor) and downstream signaling protein STAT3 (signal
transducer and activator of transcription 3) were also
increased in SSc epidermis, consistent with feedback activa-
tion of SSc epidermis by dermal fibroblasts through HGF.
Signaling through the stress-induced MAPK was investi-
gated further by staining of sections for phospho-stress-
activated protein kinase (SAPK)/c-Jun N-terminal kinase
(JNK), the MAPK upstream of c-Jun. Phospho-SAPK/JNK was
found to be strongly expressed in the cytoplasm of basal cells
in the SSc epidermis (n¼4) and was nonexpressed in control
epidermis (n¼ 4; Figure 5). The phosphorylated form of c-Jun
(Ser63), which had been identified as increased in SSc in
phosphorylation arrays, was also studied and, in keeping with
activation by SAPK/JNK, was found to be present in both
cytoplasmic and nuclear basal cells in SSc epidermis, but
absent from controls (both n¼4; Figure 5). The phosphoryla-
tion of p38 MAPK was also observed in cytoplasm of basal
cells in SSc epidermis, consistent with active p38 signal
transduction in SSc keratinocytes; however, no phosphoryla-
tion of p38 MAPK was observed in normal epidermis. In
general, these results support the activation of stress-induced
MAPK in SSc epidermis.
In addition, disease and control biopsies were stained for
phosphorylated c-Met, because of the importance of HGF
and c-Met in fibroblast–keratinocyte signaling. In the SSc
epidermis (n¼ 4), phosphorylated c-Met (Y1003) was in-
creased, with positive staining throughout the disease
epidermis, consistent with increased HGF-induced signaling
in the disease (Figure 6).
DISCUSSION
Tissue fibrosis caused by the excessive deposition of
extracellular matrix is a common feature of connective tissue
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Figure 3. Fibroblast activation by systemic sclerosis (SSc) epidermal layer is
IL-1 dependant. Normal dermal fibroblasts were cultured within fibroblast-
populated collagen lattices (FPCLs) in the presence of SSc epidermal layer
(n¼4). As before, FPCL contraction was observed after 48 hours of co-culture.
(a, b) Addition of IL-1 receptor antagonist (IL-1ra; 100 nM) at baseline
antagonized FPCL contraction (Po0.005). (c) Co-culture of FPCLs with SSc
epidermal layer did not lead to induction of IL-1a in fibroblasts as measured
by western blot.
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diseases, notably scleroderma SSc. Evidence suggests that
complex intracellular interactions involving immune cells,
endothelial cells, and fibroblasts are important pathogenic
events. However, the role of cellular events involving
epithelial cells in initiating and maintaining fibrosis has not
been extensively explored in the disease, although previous
studies show elevated levels of ET-1 (Tabata et al., 2000),
monocyte chemoattractant protein 1, TGF-b, vascular en-
dothelial growth factor, and IL-21 receptor in SSc epidermis
(Rudnicka et al., 1994; Distler et al., 2001, 2005; Davies
et al., 2006). The objective of this study was to investigate the
role of epidermal activation in SSc.
We confirmed that in SSc epidermal keratinocytes have an
altered phenotype showing delayed differentiation and
expression of K6 and K16 normally restricted to wound
healing environments, and found that IL-1a, which initiates
keratinocyte activation after injury, is greatly increased in SSc
epidermis. In addition, stress signaling MAPKs, c-Jun and
p38, which are downstream of IL-1a, were induced in SSc
epidermis. The changes in keratin expression were observed
in both clinically involved skin taken from the forearm and in
clinically uninvolved skin biopsied from the inter-scapular
region. It is likely that the epidermal changes are contributing
to the systemic features of the disease, and more specifically
seem capable of inducing fibroblast activation.
In fact epithelial–mesenchymal interactions are well-
recognized phenomena in scars and wound environments.
Wound healing is a highly complex cellular and bio-
chemical event. An initial inflammatory phase occurs after
injury to the resident epidermal keratinocytes, which release
IL-1a (Werner et al., 2007) that in turn induces a cascade
of secondary cytokines and chemokines, including IL-6,
IL-8, IL-10, tumor necrosis factor-a, TGF-b, ET-1, vascular
endothelial growth factor, and monocyte chemoattractant
protein 1 (Engelhardt et al., 1998; Uchi et al., 2000; Gillitzer
and Goebeler, 2001; Sugawara et al., 2001), in a number of
cell types including fibroblasts and endothelial cells. IL-1a
released by keratinocytes at the wound margin initiates
keratinocyte–fibroblast interaction and leads to the induction
of GM-CSF and keratinocyte growth factor in local fibroblasts
(Florin et al., 2004). IL-1a release by keratinocytes is also
responsible for the induction of K6 in the interfollicular
epidermis (Komine et al., 2001). During later stages of wound
remodeling, both ET-1 and TGF-b have a role in extracellular
matrix deposition, myofibroblast differentiation, and tissue
remodeling (Shephard et al., 2004; Horstmeyer et al., 2005).
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Figure 4. Fibroblast activation by systemic sclerosis (SSc) epidermal cells requires induction of transforming growth factor-b (TGF-b) and endothelin-1
(ET-1) in fibroblasts. (a) As before, fibroblast populated collagen lattice (FPCL) contraction was induced by co-culture with SSc epidermal cell layer (n¼3)
for 24 hours after release of pre-stressed gels. (b) Addition of the endothelin receptor antagonist bosentan (10mM) at baseline antagonized FPCL contraction
by SSc epidermal cells (Po0.02). Protein extracts of the FPCL revealed induction of fibroblast ET-1 and TGF-b expression by co-culture with SSc epidermis.
(c) ET-1 induction in FPCLs by co-culture with SSc epidermis was blocked by the addition of bosentan at baseline. Treatment of FPCLs with TGF-b also led
to (a) contraction and (c) induction of ET-1 in fibroblasts. (d) Antagonism of TGF-b by neutralizing anti-TGF-b antibody 1d11 (1 mgml–1) antagonized
FPCL contraction by SSc epidermis (n¼3) (Po0.01) and by TGF-b (Po0.05).
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ET-1 induces collagen type I and type III in fibroblast and
promotes contraction (Shi-Wen et al., 2001, 2004). Numer-
ous studies have identified both TGF-b and ET-1 as pro-
fibrotic mediators.
In an attempt to elucidate the influences of SSc epidermal
keratinocytes on underlying fibroblasts, we used a simple
model in which whole epidermal sheet is suspended within a
collagen-embedded fibroblast gel. We found that SSc
epidermal sheets strongly promoted fibroblast activation,
causing contractility and the induction of CTGF. Co-culture
of SSc epidermis with fibroblasts also led to induction of ET-1
and TGF-b in fibroblasts. These changes were antagonized by
exogenous IL-1ra, consistent with the initiation of keratino-
cyte–fibroblast interactions by keratinocyte-derived IL-1a. We
propose a model in which the activated epidermis in SSc
initiates the production of pro-fibrotic mediators in local
fibroblast through release of IL-1a. Erythema and edema are
well-recognized clinical observations in patients with early
severe SSc and they are also consistent with this model of
epithelial IL-1a upregulation.
Work from Wright’s group (Kawaguchi et al., 1999) has
previously demonstrated altered IL-1a expression in SSc,
showing constitutive expression of IL-1 mRNA and pre-IL-1a
protein in SSc fibroblasts (Kawaguchi, 1994), and depen-
dence on IL-1a for maintenance of the pro-fibrotic phenotype
in SSc. Moreover, IL-1a overexpression in normal fibroblasts
resulted in the development of an SSc fibroblast phenotype
(Kawaguchi et al., 2004). Our results are not inconsistent with
these findings because keratinocyte-derived IL-1a could
initiate IL-1 autoinduction in local fibroblasts or maintain
IL-1a-dependent fibroblast activation. In addition, an asso-
ciation of a single-nucleotide polymorphism in the promoter
region of IL-1a gene has been reported in SSc (Hutyrova´
et al., 2004), and a recent study analyzing cytokine ex-
pression profiles in SSc has revealed a significant increase in
plasma levels of IL-1a protein, but not IL-1b, in scleroderma
patients compared with controls (Duan et al., 2008).
HGF regulates cell growth, motility, and morphogenesis
by activating a tyrosine kinase signaling cascade after binding
to the receptor and proto-oncogene c-Met (Naldini et al.,
1991). HGF is secreted by mesenchymal cells after injury and
acts as a multifunctional cytokine on cells of epithelial origin.
Its ability to stimulate mitogenesis, cell motility, and matrix
invasion suggests a central role in epithelial repair and tissue
regeneration. Previous studies show that HGF secretion is
increased in SSc fibroblasts and that IL-1a is an important
inducer of HGF in these cells (Kawaguchi et al., 2002). Using
phosphorylation arrays we show that in SSc epidermal layer
the HGF receptor c-Met is activated by phosphorylation at an
HGF-dependent phosphorylation site. Therefore, our idea is
that in SSc dermal fibroblasts are exerting feedback regulation
of epidermal cells through HGF/c-Met.
Table 1. Phosphorylation sites of increased abundance in SSc epidermis compared with control epidermis
Fold change
in SSc
Phosphorylation
site Full target protein name
Swiss protein
number
P-value o
(t-test)
5.55 S70 Tyrosine hydroxylase isoform a P07101 NS
2.89 Y1003 c-Met (hepatocyte growth factor receptor-tyrosine kinase) P08581 0.05
2.63 Pan-specific Protein-serine phosphatase 4 - regulatory subunit (PPX/A02) Q8TF05 0.0005
2.62 S605 Synapsin 1 isoform Ia P17600 NS
2.57 S674 Protein-serine kinase C Z P24723 0.04
2.43 Pan-specific Male germ cell-associated protein-serine kinase P20794 NS
2.38 Pan-specific Wee1 protein-tyrosine kinase P30291 NS
2.37 S63 Jun proto-oncogene-encoded AP1 transcription factor P05412 0.02
2.29 Pan-specific NIMA (never-in-mitosis)-related protein-serine kinase 7 Q8TDX7 0.003
2.23 T514 Protein-serine kinase C g P05129 NS
2.18 Y705 Signal transducer and activator of transcription 3 P40763 0.05
2.18 Pan-specific Dual specificity protein kinase P33981 0.02
2.18 T674 Protein-serine kinase C g P05129 0.04
2.17 Pan-specific Integrin-linked protein-serine kinase 1 Q13418 0.05
2.15 Y1189/Y1190 Insulin receptor/insulin-like growth factor 1 receptor P06213 NS
2.13 T180+Y182 Mitogen-activated protein-serine kinase p38 a Q16539 0.05
2.10 Pan-specific PCTAIRE-1 protein-serine kinase Q00536 0.02
2.09 Pan-specific NIMA (never-in-mitosis)-related protein-serine kinase 4 P51957 NS
2.07 Pan-specific Polo-like protein kinase 3 Q9H4B4 NS
Abbreviations: NS, not significant; SSc, systemic sclerosis. Phosphorylation arrays were used for comparison of 628 potential phosphorylation sites in SSc
and control epidermal biopsies (both n=4). Correction for multiple testing was performed using significance analysis of microarrays (Excel) software, using a
two-class unpaired test with 5,000 permutations, and t-test as the computed statistic. Phosphorylation sites of more than 2-fold increase in SSc are shown.
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We found abnormal activation of the epidermis in SSc,
which in turn seems capable of stimulating fibroblasts
through IL-1a. We propose a model of chronic injury to
and activation of the epidermis in SSc, which in turn
promotes and sustains fibroblast activation and scarring.
These results have therapeutic implications because epithe-
lial–fibroblast interactions could be blocked by biologic
therapies and specifically IL-1a antagonized by recombinant
IL-1ra or monoclonal anti-IL-1 in SSc.
MATERIALS AND METHODS
Patient selection
SSc was defined and classified according to the internationally
agreed guidelines (Subcommittee for scleroderma criteria of the
American Rheumatism Association Diagnostic and Therapeutic
Criteria Committee, 1980). Patients selected for inclusion in the
study were from the diffuse SSc subset (skin changes proximal to
elbows and involving the trunk) and were within 2 years of the onset
of skin changes. Local institutional approval was obtained for the
study from the ethical committee of the Royal Free Hospital. Patients
and healthy controls gave written informed consent to participate in
the study and we adhered to the guidelines of the Declaration of
Helsinki Principles.
FPCL contraction studies
FPCLs were cultured in 24-well plates. Wells were pre-coated with
BSA. Trypsinized normal dermal fibroblasts were suspended in
DMEM medium and mixed with collagen solution (1 part of 0.2 M
HEPES, pH 8.0, 4 parts rat dermal collagen type I (First Link UK,
West Midlands, UK) and 5 parts of DMEM), yielding a final
concentration of 80,000 cellsml–1 and 1.2mgml–1 type I collagen.
Collagen/cell suspension (1ml) was added to each well.
Full-thickness punch biopsies (4mm) were obtained from the
forearm skin of patients with diffuse SSc and from healthy control
subjects (both n¼ 6). The epidermis was separated from dermal layer
after incubation with 0.05mgml–1 trypsin in 10ml of phosphate-
buffered saline (PBS) at 37 1C for 2 hours. Epidermal sheets were
removed using fine forceps and allowed to settle into FPCLs before
polymerization of the collagen gel. Control FPCLs were left
untreated. Other FPCLs were treated with TGF-b (4 ngml–1) (R&D
Systems, Minneapolis, MN). Further studies were performed to
establish the importance of TGF-b, ET-1, and IL-1a in mediating
FPCL contraction by SSc epidermis. In each instance, paired 4mm
biopsies were taken from each of three SSc patients and three
healthy controls. Paired SSc and control biopsies were co-cultured
with FPCL with or without addition of inhibitors/antagonists as
follows: neutralizing anti-TGF-b antibody 1D11 (1mgml–1; R&D
Table 2. Phosphorylation sites of decreased abundance in SSc epidermis compared with control epidermis
Fold change
in SSc
Phosphorylation
site Full target protein name
Swiss protein
number
P-value o
(t-test)
0.50 Pan-specific Calcium/calmodulin-dependent protein-serine kinase 2 g Q05682 NS
0.48 S789 Caldesmon O95835 NS
0.47 Pan-specific Large tumor suppressor 1 protein-serine kinase (WARTS) P08107 NS
0.46 Pan-specific Heat shock 70 kDa protein 1 Q8IU85 NS
0.45 Pan-specific Calcium/calmodulin-dependent protein-serine kinase 1 d P51636 NS
0.44 S36 Caveolin 2 P08575 0.04
0.44 Pan-specific Leukocyte common antigen CD45 receptor-tyrosine phosphatase (LCA, T200) Q9P286 0.02
0.43 Pan-specific p21-activated serine kinase 5 (Serine/threonine-protein kinase PAK 7) Q13554 NS
0.43 Pan-specific Calcium/calmodulin-dependent protein-serine kinase 2 b Q00535 NS
0.42 Pan-specific Cyclin-dependent protein-serine kinase 5 P16220 NS
0.41 S129+S133 cAMP response element binding protein 1 Q14004 0.05
0.41 Pan-specific Cell division cycle 2-like protein-serine kinase 5 P35568 0.008
0.40 Y612 Insulin receptor substrate 1 Q9UQM7 NS
0.40 T286 Calcium/calmodulin-dependent protein-serine kinase 2 a P30519 0.05
0.40 Pan-specific Heme oxygenase 2 P30305 0.003
0.40 Pan-specific Cell division cycle 25B phosphatase P35354 0.01
0.40 Pan-specific Cyclo-oxygenase 2 (prostaglandin G/H synthase 2 precursor) P11802 0.005
0.39 Pan-specific Cyclin-dependent protein-serine kinase 4 O60674 0.03
0.39 Pan-specific Janus protein-tyrosine kinase 2 P51878 NS
0.36 Pan-specific Caspase 5 (ICH3 protease, ICE(rel)-III) P42574 0.01
0.34 Pan-specific Pro-caspase 3 (apopain, cysteine protease CPP32) Q07817 0.02
0.33 Pan-specific Bcl2-like protein 1 Q13574 NS
0.31 Pan-specific Diacylglycerol kinase z Q05682 NS
Abbreviations: NS, not significant; SSc, systemic sclerosis. Phosphorylation sites of o0.5 abundance in SSc are shown.
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Systems), bosentan (10 mM; Actelion, Allschwil, Switzerland), or IL-
1ra (100 ngml–1; IMR-245; Imgenex, San Diego, CA). FPCLs were
left attached to wells overnight to allow firm attachment and
mechanical stress to develop within fibroblasts, and then released
from the well. FPCLs were cultured for a further 24 hours and
contraction was assessed by photography and measurement of
maximum diameter, expressed as a percentage of baseline diameter
(well diameter).
Western blot assay
Western blot analysis of fibroblast gels was performed to determine
the levels of TGF-b, CTGF, ET-1, a-smooth muscle actin, and IL-1a. In
these studies, FPCLs were lysed in 200ml of Western buffer (Laemmli
buffer), after culture with or without SSc and control epidermis, and
then heated for 5minutes at 95 1C and spun for 5minutes to remove
insoluble material. Samples were loaded onto 12% Tris-glycine gels
(Invitrogen, Paisley, UK) at 12ml per well and run with broad-range
protein markers. After transfer to a nitrocellulose membrane (Hybond-C
extra; Amersham Pharmacia Biotech, Chalfont, Bucks, UK), the
membranes were blocked in PBS-Tween with 5% marvel milk for
2 hours. The membranes were incubated overnight with specific
antibodies against anti-TGF-b (sc-146, rabbit; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-CTGF (sc-14939, goat; Santa Cruz
Biotechnology), anti-a-smooth muscle actin (MO851, mouse; DAKO),
anti-ET-1 (T-4049, rabbit; Bachem), anti-IL-1a (sc-9983, mouse; Santa
Cruz Biotechnology), anti-GAPDH (ab8245-100, mouse; Abcam),
and anti-b-actin (A 5441, mouse; Sigma). The membranes were then
washed and incubated with appropriate horseradish peroxidase-
conjugated secondary antibodies. The membrane was developed
using chemiluminescent substrate (Amersham Pharmacia Biotech)
was and the blots were developed against photographic film
(Hyperfilm ECL; Amersham Pharmacia Biotech).
Immunohistochemistry
Immunostaining for keratin differentiation markers was performed
using 5 mM paraffin sections of material from six patients with
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Figure 5. Activation of stress-induced mitogen-activated protein kinase
(MAPK) in systemic sclerosis (SSc). Immunofluorescence staining of stress-
activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK), c-Jun, and p38
phosphorylation was observed in SSc epidermis (n¼ 4). Double staining of
MAPK, with blue color nuclear stain (4,6-diamidino-2-phenylindoleDAPI)
and red color for MAPK. Phosphorylation of SAPK/JNK was observed in the
cytoplasm of basal cells in SSc epidermis (c), merged (a), and only a low level
of basal cell phosphorylation of SAPK/JNK was observed in normal epidermis
(d), merged (b). AP-1 transcriptional factor family c-Jun phosphorylation was
also observed in basal layer of the epidermis in SSc (n¼4) (g), merged (e).
Three or more positive cells of c-Jun were observed in normal epidermis
(n¼4) (h), merged (f). Strong cytoplasmic staining of phosph-p38 MAPK was
also observed in basal layer of the epidermis in SSc patients (n¼ 4), consistent
with active p38 signaling in the disease keratinocytes (k), merged (i). In
normal skin, no phosphorylation of p38 expression was observed (l), merged
(j). Scale bar¼50 mm.
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Figure 6. Increased phosphorylation of c-Met in involved systemic sclerosis
(SSc) epidermis. (a, c) Immunofluorescence staining of c-Met (Y1003) red and
4,6-diamidino-2-phenylindole (DAPI) blue. Increased phosphorylation of
c-Met (Y1003) in SSc epidermis (n¼ 4) (c), and merged (a), was observed
throughout SSc epidermis. (b, d) Only a low level of c-Met phosphorylation
was observed in control epidermis (n¼ 4). Scale bar¼20 mM.
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recent-onset diffuse SSc and from the forearms of six healthy control
subjects. Paraffin-embedded skin biopsies were de-waxed and
rehydrated, and washed in PBS. Antigen retrieval was performed
using citrate buffer. Nonspecific binding was blocked with 10%
serum for 30minutes at room temperature. The sections were
incubated with primary mouse monoclonal antibodies directed
against human K14 (RTU-LL002; Novocastra Laboratories,
Newcastle upon Tyne, UK), K6, and K16 (LL025; Lab Vision
Corporation, Freemont, CA) for 1 hour at room temperature. Sections
were further incubated with secondary anti-mouse for 1 hour, before
incubation with Avidn/Biotinylated enzyme Complex (ABC, Vector
Laboratories, Burlingame, CA) for 30minutes and developed with
AEC kit (Vector Laboratories, Burlingame, CA).
Assay for SSc and control epidermal TGF-b, ET-1, and IL-1
by ELISA
Forearm skin punch biopsies (4mm) were obtained from six
additional patients with recent-onset diffuse SSc and six healthy
control subjects. Biopsies were snap-frozen in isopentane in liquid
nitrogen and epidermal layers were separated by surgical dissection
of the frozen material. Epidermal discs were lysed in buffer
containing 10mM Tris-buffered saline, 0.1% SDS, 1% Nonidet
p40, 5mM EDTA, and one tablet of Complete Mini Protease Inhibitor
(Roche Applied Science, Burgess Hill, UK). A micro-homogenizer
was used to break down the samples on ice. The samples were
centrifuged for 5minutes to pellet debris. Total epidermal TGF-b free
and associated with latency-associated peptide, ET-1, and IL-1a
were assayed by ELISA (all from R&D Systems).
Measurement of phosphorylation of signaling proteins in SSc
and control epidermis
Whole skin biopsy material from SSc and controls (both n¼ 4) was
immediately frozen in liquid nitrogen after excision. Epidermal cell
layer was dissected surgically from the frozen material. The tissue
processing and phospho-kinase screening was performed by Kinexus
(Vancouver, Canada).
Immunohistochemical staining for signaling molecules was
performed on formalin-fixed sections to confirm changes in the
phosphorylation status of c-Jun, p38, and c-Met, using biopsies from
four SSc patients and four controls. For immunofluorescence,
sections were permeabilized by washing three times in cold PBS
containing 0.3% Triton X-100 at room temperature for 5minutes and
then further washing in PBS containing 0.1% Tween. Nonspecific
binding sides were blocked with 3% BSA, 10% serum in PBS with
Tween for 30minutes. Sections were immunostained with antibody
against phospho-SAPK/JNK (Tyr 185 and Try 182), phospho-p38
MAPK (both from Cell Signaling Technology, Danvers, MA),
phospho-c-Jun (Ser63; Santa Cruz Biotechnology), and phosphor-c-
Met (Y1003; Abcam) overnight at 4 1C. Sections were incubated with
Alexa Fluor 568 and 594 labeled species-specific secondary
antibodies (Molecular Probes, Invitrogen, Eugene, OR, USA)
(1:1,000) for 1 hour. As a negative control, samples were incubated
with blocking buffer. Nuclei were stained for 4,6-diamidino-2-
phenylindole (Sigma-Aldrich) for 10minutes. Glass coverslips were
mounted onto slides with Vector aqueous antifade fluorescent
mounting medium (Vector Laboratories, Burlingame, CA) and sealed
with nail polish. Sections were imaged with Axioplan Zeiss
microscope (Zeiss, Oberkochen, Germany) at  40 magnification.
Statistical analysis
For the phosphorylation array data, statistical analysis and correction
for multiple testing were performed using Significance Analysis of
Microarrays (Excel) software for 628 sites detected by the array data,
and analyzed using a two-class unpaired test with 5,000 permuta-
tions and t-test as the computed statistic (Tusher et al., 2001). A fold
change of two was selected as the threshold for biological relevance
with a false discovery rate of 15% (de Winter, 2009).
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